Your browser doesn't support javascript.
loading
HuR/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis.
Palomo-Irigoyen, Marta; Pérez-Andrés, Encarni; Iruarrizaga-Lejarreta, Marta; Barreira-Manrique, Adrián; Tamayo-Caro, Miguel; Vila-Vecilla, Laura; Moreno-Cugnon, Leire; Beitia, Nagore; Medrano, Daniela; Fernández-Ramos, David; Lozano, Juan José; Okawa, Satoshi; Lavín, José L; Martín-Martín, Natalia; Sutherland, James D; de Juan, Virginia Guitiérez; Gonzalez-Lopez, Monika; Macías-Cámara, Nuria; Mosén-Ansorena, David; Laraba, Liyam; Hanemann, C Oliver; Ercolano, Emanuela; Parkinson, David B; Schultz, Christopher W; Araúzo-Bravo, Marcos J; Ascensión, Alex M; Gerovska, Daniela; Iribar, Haizea; Izeta, Ander; Pytel, Peter; Krastel, Philipp; Provenzani, Alessandro; Seneci, Pierfausto; Carrasco, Ruben D; Del Sol, Antonio; Martinez-Chantar, María Luz; Barrio, Rosa; Serra, Eduard; Lazaro, Conxi; Flanagan, Adrienne M; Gorospe, Myriam; Ratner, Nancy; Aransay, Ana M; Carracedo, Arkaitz; Varela-Rey, Marta; Woodhoo, Ashwin.
Afiliación
  • Palomo-Irigoyen M; Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain.
  • Pérez-Andrés E; Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain.
  • Iruarrizaga-Lejarreta M; Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain.
  • Barreira-Manrique A; Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain.
  • Tamayo-Caro M; Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain.
  • Vila-Vecilla L; Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain.
  • Moreno-Cugnon L; Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain.
  • Beitia N; Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain.
  • Medrano D; Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain.
  • Fernández-Ramos D; Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain.
  • Lozano JJ; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.
  • Okawa S; Bioinformatic Platform, CIBERehd, Instituto de Salud Carlos III, Barcelona, Spain.
  • Lavín JL; Computational Biology Group, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Belvaux, Luxembourg.
  • Martín-Martín N; Integrated BioBank of Luxembourg, Dudelange, Luxembourg.
  • Sutherland JD; Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain.
  • de Juan VG; Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain.
  • Gonzalez-Lopez M; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.
  • Macías-Cámara N; Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain.
  • Mosén-Ansorena D; Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain.
  • Laraba L; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.
  • Hanemann CO; Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain.
  • Ercolano E; Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain.
  • Parkinson DB; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.
  • Schultz CW; Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain.
  • Araúzo-Bravo MJ; Institute of Translational and Stratified Medicine, Faculty of Medicine and Dentistry, Plymouth University, Derriford Research Facility, Devon, United Kingdom.
  • Ascensión AM; Institute of Translational and Stratified Medicine, Faculty of Medicine and Dentistry, Plymouth University, Derriford Research Facility, Devon, United Kingdom.
  • Gerovska D; Institute of Translational and Stratified Medicine, Faculty of Medicine and Dentistry, Plymouth University, Derriford Research Facility, Devon, United Kingdom.
  • Iribar H; Institute of Translational and Stratified Medicine, Faculty of Medicine and Dentistry, Plymouth University, Derriford Research Facility, Devon, United Kingdom.
  • Izeta A; Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Pytel P; Computational Biology and Systems Biomedicine, Biodonostia Health Research Institute, San Sebastián, Spain.
  • Krastel P; IKERBASQUE, Basque Foundation for Science, Bilbao, Spain.
  • Provenzani A; Computational Biology and Systems Biomedicine, Biodonostia Health Research Institute, San Sebastián, Spain.
  • Seneci P; Computational Biology and Systems Biomedicine, Biodonostia Health Research Institute, San Sebastián, Spain.
  • Carrasco RD; Tissue Engineering Laboratory, Bioengineering Area, Instituto Biodonostia, San Sebastián, Spain.
  • Del Sol A; Tissue Engineering Laboratory, Bioengineering Area, Instituto Biodonostia, San Sebastián, Spain.
  • Martinez-Chantar ML; Department of Pathology, University of Chicago, Chicago, Illinois, USA.
  • Barrio R; Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Serra E; Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy.
  • Lazaro C; Chemistry Department, University of Milan, Milan, Italy.
  • Flanagan AM; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
  • Gorospe M; Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain.
  • Ratner N; Computational Biology Group, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Belvaux, Luxembourg.
  • Aransay AM; IKERBASQUE, Basque Foundation for Science, Bilbao, Spain.
  • Carracedo A; Moscow Institute of Physics and Technology, Dolgoprudny, Russia.
  • Varela-Rey M; Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain.
  • Woodhoo A; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.
J Clin Invest ; 130(7): 3848-3864, 2020 07 01.
Article en En | MEDLINE | ID: mdl-32315290
ABSTRACT
Cancer cells can develop a strong addiction to discrete molecular regulators, which control the aberrant gene expression programs that drive and maintain the cancer phenotype. Here, we report the identification of the RNA-binding protein HuR/ELAVL1 as a central oncogenic driver for malignant peripheral nerve sheath tumors (MPNSTs), which are highly aggressive sarcomas that originate from cells of the Schwann cell lineage. HuR was found to be highly elevated and bound to a multitude of cancer-associated transcripts in human MPNST samples. Accordingly, genetic and pharmacological inhibition of HuR had potent cytostatic and cytotoxic effects on tumor growth, and strongly suppressed metastatic capacity in vivo. Importantly, we linked the profound tumorigenic function of HuR to its ability to simultaneously regulate multiple essential oncogenic pathways in MPNST cells, including the Wnt/ß-catenin, YAP/TAZ, RB/E2F, and BET pathways, which converge on key transcriptional networks. Given the exceptional dependency of MPNST cells on HuR for survival, proliferation, and dissemination, we propose that HuR represents a promising therapeutic target for MPNST treatment.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Transducción de Señal / Neoplasias de la Vaina del Nervio / Proliferación Celular / Carcinogénesis / Proteína 1 Similar a ELAV / Proteínas de Neoplasias Límite: Animals / Humans Idioma: En Revista: J Clin Invest Año: 2020 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Transducción de Señal / Neoplasias de la Vaina del Nervio / Proliferación Celular / Carcinogénesis / Proteína 1 Similar a ELAV / Proteínas de Neoplasias Límite: Animals / Humans Idioma: En Revista: J Clin Invest Año: 2020 Tipo del documento: Article País de afiliación: España